Supernus Pharmaceuticals Company Profile (NASDAQ:SUPN)

About Supernus Pharmaceuticals (NASDAQ:SUPN)

Supernus Pharmaceuticals logoSupernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy. In addition, it is developing multiple product candidates in psychiatry to address unmet medical needs and market opportunities for the treatment of impulsive aggression (IA) and for the treatment of attention deficit hyperactivity disorder (ADHD). It is developing SPN-810 (molindone hydrochloride) to treat IA in patients having ADHD. It is developing SPN-812 (viloxazine hydrochloride) as a candidate to treat patients having ADHD. The Company's neurology portfolio consists of Oxtellar XR and Trokendi XR, which are the first once-daily extended release oxcarbazepine and topiramate products, respectively, indicated for epilepsy in the United States market.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Specialty & Advanced Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:SUPN
  • CUSIP: 86845910
  • Web:
  • Market Cap: $2.12466 billion
  • Outstanding Shares: 50,282,000
Average Prices:
  • 50 Day Moving Avg: $41.78
  • 200 Day Moving Avg: $32.37
  • 52 Week Range: $17.25 - $44.95
  • Trailing P/E Ratio: 22.70
  • Foreward P/E Ratio: 25.73
  • P/E Growth: 1.55
Sales & Book Value:
  • Annual Revenue: $228.39 million
  • Price / Sales: 9.29
  • Book Value: $4.10 per share
  • Price / Book: 10.29
  • EBIDTA: $67.28 million
  • Net Margins: 42.46%
  • Return on Equity: 31.79%
  • Return on Assets: 19.08%
  • Debt-to-Equity Ratio: 0.02%
  • Current Ratio: 1.83%
  • Quick Ratio: 1.59%
  • Average Volume: 637,862 shs.
  • Beta: 1.34
  • Short Ratio: 5.1
Frequently Asked Questions for Supernus Pharmaceuticals (NASDAQ:SUPN)

What is Supernus Pharmaceuticals' stock symbol?

Supernus Pharmaceuticals trades on the NASDAQ under the ticker symbol "SUPN."

How were Supernus Pharmaceuticals' earnings last quarter?

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) issued its earnings results on Tuesday, May, 9th. The company reported $0.19 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.22 by $0.03. The business had revenue of $57.58 million for the quarter, compared to analysts' expectations of $57.91 million. Supernus Pharmaceuticals had a return on equity of 31.79% and a net margin of 42.46%. View Supernus Pharmaceuticals' Earnings History.

When will Supernus Pharmaceuticals make its next earnings announcement?

Supernus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, July, 31st 2017. View Earnings Estimates for Supernus Pharmaceuticals.

Where is Supernus Pharmaceuticals' stock going? Where will Supernus Pharmaceuticals' stock price be in 2017?

6 brokers have issued 12 month price objectives for Supernus Pharmaceuticals' stock. Their forecasts range from $34.00 to $51.00. On average, they expect Supernus Pharmaceuticals' stock price to reach $45.67 in the next year. View Analyst Ratings for Supernus Pharmaceuticals.

What are analysts saying about Supernus Pharmaceuticals stock?

Here are some recent quotes from research analysts about Supernus Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. " (7/18/2017)
  • 2. Jefferies Group LLC analysts commented, "Following Monday's Zydus settlement, SUPN reached a similar agreement with TEVA on the Trokendi XR (TXR) patent challenge ' allowing generic entry starting January 2023. There is now much more certainty in SUPN's ability to maintain cash flows from 76% of its current epilepsy franchises at least through 2022 and another 24% through 2027 (OXR), bridging to the latestage pipeline, which should come online in 2020. Importantly, SUPN fits with our M&A thesis." (3/8/2017)
  • 3. Cantor Fitzgerald analysts commented, "SUPN announced the settlement of a Paragraph 4 challenge to Trokendi XR patents by Zydus allowing generic entry on or before 1/1/2023." (3/7/2017)

Who are some of Supernus Pharmaceuticals' key competitors?

Who are Supernus Pharmaceuticals' key executives?

Supernus Pharmaceuticals' management team includes the folowing people:

  • Charles W. Newhall III, Independent Chairman of the Board
  • Jack A. Khattar, President, Chief Executive Officer, Secretary, Director
  • Gregory S. Patrick, Chief Financial Officer, Vice President
  • Stefan K. F. Schwabe M.D. Ph.D., Executive Vice-President - Research and Development, Chief Medical Officer
  • Padmanabh P. Bhatt Ph.D., Senior Vice President - Intellectual Property, Chief Scientific Officer
  • Victor Vaughn, Senior Vice President - Sales and Marketing
  • Georges Gemayel Ph.D., Independent Director
  • Frederick M. Hudson CPA, Independent Director
  • William A. Nuerge, Independent Director
  • John M. Siebert Ph.D., Independent Director

Who owns Supernus Pharmaceuticals stock?

Supernus Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Capital Management Corp VA (0.23%), Bank of Montreal Can (0.09%), US Bancorp DE (0.08%), Juncture Wealth Strategies LLC (0.07%), Franklin Street Advisors Inc. NC (0.06%) and Capital Impact Advisors LLC (0.06%). Company insiders that own Supernus Pharmaceuticals stock include Gregory S Patrick, M James Barrett and Padmanabh P Bhatt. View Institutional Ownership Trends for Supernus Pharmaceuticals.

Who sold Supernus Pharmaceuticals stock? Who is selling Supernus Pharmaceuticals stock?

Supernus Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Juncture Wealth Strategies LLC, Capital Impact Advisors LLC, Capital Management Corp VA, US Bancorp DE, Franklin Street Advisors Inc. NC, Capstone Asset Management Co. and Thomson Horstmann & Bryant Inc.. Company insiders that have sold Supernus Pharmaceuticals stock in the last year include Gregory S Patrick and Padmanabh P Bhatt. View Insider Buying and Selling for Supernus Pharmaceuticals.

Who bought Supernus Pharmaceuticals stock? Who is buying Supernus Pharmaceuticals stock?

Supernus Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Legato Capital Management LLC, Adams Diversified Equity Fund Inc., NEXT Financial Group Inc, Sheets Smith Wealth Management, Eqis Capital Management Inc., Creative Planning, Aperio Group LLC and State of Alaska Department of Revenue. View Insider Buying and Selling for Supernus Pharmaceuticals.

How do I buy Supernus Pharmaceuticals stock?

Shares of Supernus Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Supernus Pharmaceuticals' stock price today?

One share of Supernus Pharmaceuticals stock can currently be purchased for approximately $42.20.

MarketBeat Community Rating for Supernus Pharmaceuticals (NASDAQ SUPN)
Community Ranking:  3.5 out of 5 (   )
Outperform Votes:  176 (Vote Outperform)
Underperform Votes:  78 (Vote Underperform)
Total Votes:  254
MarketBeat's community ratings are surveys of what our community members think about Supernus Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Supernus Pharmaceuticals (NASDAQ:SUPN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $45.67 (8.21% upside)

Analysts' Ratings History for Supernus Pharmaceuticals (NASDAQ:SUPN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/18/2017Stifel NicolausReiterated RatingBuy$36.00 -> $47.00MediumView Rating Details
7/17/2017Piper Jaffray CompaniesDowngradeOverweight -> Neutral$46.00HighView Rating Details
7/14/2017Janney Montgomery ScottInitiated CoverageNeutral -> Neutral$47.00LowView Rating Details
7/5/2017Cantor FitzgeraldBoost Price TargetBuy$34.00 -> $49.00MediumView Rating Details
6/28/2017Jefferies Group LLCBoost Price TargetBuy$45.00 -> $51.00HighView Rating Details
5/11/2017Cowen and CompanyBoost Price TargetOutperform$31.00 -> $34.00LowView Rating Details
7/18/2016Northland SecuritiesDowngradeOutperform -> Market Perform$24.00N/AView Rating Details
(Data available from 7/22/2015 forward)


Earnings History for Supernus Pharmaceuticals (NASDAQ:SUPN)
Earnings by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)
Earnings History by Quarter for Supernus Pharmaceuticals (NASDAQ SUPN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017$0.22$0.19$57.91 million$57.58 millionViewListenView Earnings Details
8/2/2016Q2$0.13$0.18$49.67 million$50.40 millionViewListenView Earnings Details
5/3/2016Q1$0.09$0.08$45.33 million$43.00 millionViewListenView Earnings Details
3/2/2016Q4$0.06$0.14$42.93 million$42.70 millionViewListenView Earnings Details
11/3/2015Q315$0.02$0.08$37.93 million$38.60 millionViewListenView Earnings Details
8/5/2015Q215$0.02$0.03$34.07 million$35.10 millionViewListenView Earnings Details
5/5/2015$0.02$0.02$29.16 million$28.13 millionViewListenView Earnings Details
11/11/2014Q314$0.36$0.39$43.10 million$52.50 millionViewN/AView Earnings Details
8/11/2014Q214($0.16)$0.08$19.85 million$29.67 millionViewN/AView Earnings Details
5/12/2014Q114($0.41)($0.38)$9.94 million$9.00 millionViewN/AView Earnings Details
3/12/2014Q413($0.55)($0.65)$7.78 million$10.30 millionViewN/AView Earnings Details
11/12/2013Q313($0.67)($0.78)$2.54 million$1.26 millionViewListenView Earnings Details
8/13/2013Q2 2013($0.65)($0.89)$0.91 million$0.28 millionViewN/AView Earnings Details
11/7/2012Q312($0.62)($0.55)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Supernus Pharmaceuticals (NASDAQ:SUPN)
2017 EPS Consensus Estimate: $1.04
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.16$0.24$0.20
Q2 20172$0.23$0.24$0.24
Q3 20171$0.24$0.24$0.24
Q4 20172$0.23$0.49$0.36
(Data provided by Zacks Investment Research)


Dividend History for Supernus Pharmaceuticals (NASDAQ:SUPN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Supernus Pharmaceuticals (NASDAQ:SUPN)
Insider Ownership Percentage: 6.70%
Institutional Ownership Percentage: 90.95%
Insider Trades by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)
Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)
Insider Trades by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/12/2017Padmanabh P BhattVPSell3,735$44.90$167,701.50View SEC Filing  
6/23/2017Padmanabh P BhattVPSell2,556$44.90$114,764.40View SEC Filing  
6/2/2017Padmanabh P BhattVPSell10,000$39.86$398,600.00View SEC Filing  
5/26/2017Padmanabh P BhattVPSell2,500$35.90$89,750.00View SEC Filing  
5/25/2017Padmanabh P BhattVPSell5,500$34.90$191,950.00View SEC Filing  
4/24/2017Gregory S PatrickCFOSell54,000$32.37$1,747,980.00View SEC Filing  
4/24/2017Padmanabh P BhattVPSell11,806$32.59$384,757.54View SEC Filing  
9/16/2016Gregory S PatrickCFOSell2,000$25.00$50,000.00View SEC Filing  
7/14/2016Gregory S. PatrickCFOSell3,395$22.00$74,690.00View SEC Filing  
4/11/2016Padmanabh P BhattVPSell30,762$16.49$507,265.38View SEC Filing  
12/9/2015Padmanabh P. BhattVPSell14,238$14.90$212,146.20View SEC Filing  
12/8/2015M James BarrettDirectorSell212,970$14.56$3,100,843.20View SEC Filing  
11/25/2015M James BarrettDirectorSell16,179$16.35$264,526.65View SEC Filing  
11/18/2015M James BarrettDirectorSell93,000$16.61$1,544,730.00View SEC Filing  
11/16/2015M James BarrettDirectorSell119,650$16.24$1,943,116.00View SEC Filing  
11/4/2015Padmanabh P BhattVPSell5,000$19.90$99,500.00View SEC Filing  
7/16/2015Gregory S PatrickCFOSell6,217$20.00$124,340.00View SEC Filing  
7/13/2015Stefan K.F. SchwabeEVPSell1,950$19.23$37,498.50View SEC Filing  
6/17/2015M James BarrettDirectorSell111,881$16.39$1,833,729.59View SEC Filing  
6/17/2015Scott D SandellMajor ShareholderSell136,597$16.50$2,253,850.50View SEC Filing  
6/16/2015M James BarrettDirectorSell55,105$16.85$928,519.25View SEC Filing  
6/16/2015Scott D SandellMajor ShareholderSell95,437$16.92$1,614,794.04View SEC Filing  
6/12/2015Stefan K.F. SchwabeEVPSell2,051$18.27$37,471.77View SEC Filing  
6/11/2015Stefan K.F. SchwabeEVPSell3,631$16.39$59,512.09View SEC Filing  
3/24/2015Jones W BryanVPSell1,900$12.00$22,800.00View SEC Filing  
8/19/2013Padmanabh BhattVPSell2,285$8.21$18,759.85View SEC Filing  
3/22/2013Michael BighamDirectorBuy35,000$5.41$189,350.00View SEC Filing  
3/21/2013John M SiebertDirectorBuy3,000$5.50$16,500.00View SEC Filing  
3/15/2013Jack A KhattarCEOBuy10,000$6.15$61,500.00View SEC Filing  
3/14/2013Gregory S PatrickCFOBuy5,000$6.95$34,750.00View SEC Filing  
12/4/2012John M SiebertDirectorBuy7,000$8.14$56,980.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Supernus Pharmaceuticals (NASDAQ:SUPN)
Latest Headlines for Supernus Pharmaceuticals (NASDAQ:SUPN)
DateHeadline logoSupernus Pharmaceuticals, Inc. (SUPN) Expected to Announce Quarterly Sales of $68.54 Million - July 20 at 3:22 PM logoSupernus to Host Second Quarter 2017 Earnings Conference Call - GlobeNewswire (press release) - July 20 at 8:13 AM logoSupernus to Host Second Quarter 2017 Earnings Conference Call - July 20 at 8:13 AM logoLightning Round: Jim Cramer Advises Viewers On Chegg, Opko Health And More - Benzinga - July 19 at 7:51 AM logoSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) VP Padmanabh P. Bhatt Sells 3,735 Shares - July 14 at 8:26 PM logoSupernus Pharmaceuticals, Inc. (SUPN) Now Covered by Janney Montgomery Scott - July 14 at 9:10 AM logoAimmune Therapeutics (AIMT) & Supernus Pharmaceuticals (SUPN) Head-To-Head Contrast - July 13 at 12:26 PM logoETFs with exposure to Supernus Pharmaceuticals, Inc. : July 12, 2017 - July 13 at 10:03 AM logoSupernus Pharmaceuticals Inc (NASDAQ:SUPN) PT Raised to $49.00 - July 9 at 8:28 PM logoSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Expected to Post FY2017 Earnings of $1.10 Per Share - July 7 at 10:52 AM logoSupernus Pharmaceuticals, Inc. to Post FY2018 Earnings of $1.93 Per Share, Cantor Fitzgerald Forecasts (SUPN) - July 6 at 11:50 AM logoStrange: Bullish SUPN Analysts Actually See -3.33% Downside - Nasdaq - July 4 at 7:43 AM logoSupernus Pharmaceuticals, Inc. (SUPN) Given Average Rating of "Buy" by Analysts - July 3 at 4:58 PM logoReviewing Supernus Pharmaceuticals (SUPN) and TherapeuticsMD (TXMD) - July 1 at 10:04 PM logoETFs with exposure to Supernus Pharmaceuticals, Inc. : June 30, 2017 - July 1 at 7:56 AM logoJefferies Group Research Analysts Cut Earnings Estimates for Supernus Pharmaceuticals, Inc. (SUPN) - June 30 at 8:43 AM logoSupernus Pharmaceuticals, Inc. (SUPN) Price Target Raised to $51.00 at Jefferies Group LLC - June 28 at 8:19 AM logoPadmanabh P. Bhatt Sells 2,556 Shares of Supernus Pharmaceuticals, Inc. (SUPN) Stock - June 27 at 7:50 PM logoFY2018 Earnings Estimate for Supernus Pharmaceuticals, Inc. (SUPN) Issued By Cantor Fitzgerald - June 26 at 7:51 AM logoBidaskClub Upgrades Supernus Pharmaceuticals, Inc. (SUPN) to "Strong-Buy" - June 24 at 3:38 PM logoSupernus Pharmaceuticals, Inc. (SUPN) Expected to Announce Quarterly Sales of $68.62 Million - June 23 at 1:00 PM logoSupernus Pharma (SUPN) Announces Partner, Shire PLC (SHPG), Granted FDA Approval for Mydayis for ADHD - June 22 at 1:53 PM logoSupernus Announces that its Partner Shire Receives FDA Approval for Mydayis™ for ADHD - June 22 at 1:53 PM logo Brokerages Expect Supernus Pharmaceuticals, Inc. (SUPN) to Announce $0.25 EPS - June 22 at 12:16 AM logoETFs with exposure to Supernus Pharmaceuticals, Inc. : June 19, 2017 - June 20 at 8:16 AM logoSupernus Pharmaceuticals, Inc. :SUPN-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017 - June 17 at 6:28 AM logoSupernus Pharmaceuticals (SUPN) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow - June 9 at 1:29 AM logoRevisiting The Investment Case On Supernus - Seeking Alpha - June 8 at 1:08 AM logoSupernus Pharmaceuticals Inc (SUPN) Given Consensus Rating of "Buy" by Brokerages - June 6 at 2:38 PM logoSupernus Pharmaceuticals Inc (SUPN) VP Sells $398,600.00 in Stock - June 5 at 7:42 PM logoSupernus Pharmaceuticals Inc to Post Q2 2017 Earnings of $0.25 Per Share, Jefferies Group Forecasts (SUPN) - June 2 at 7:06 AM logoPiper Jaffray Upgrades Supernus Pharmaceutical On Possible Label Expansion For Seizure Drug - Benzinga - June 2 at 1:09 AM logoThis Top-Rated Biotech Just Popped To A Record High On An Upgrade - June 2 at 1:09 AM logoSupernus to Present at Jefferies Healthcare Conference - June 2 at 1:09 AM logoSupernus Pharmaceuticals Inc (SUPN) Upgraded to Overweight at Piper Jaffray Companies - June 1 at 11:46 AM logoSupernus Pharmaceuticals Inc (SUPN) to Post Q3 2017 Earnings of $0.22 Per Share, Jefferies Group Forecasts - June 1 at 8:18 AM logoSupernus Pharmaceuticals' (SUPN) Buy Rating Reiterated at Jefferies Group LLC - May 31 at 12:34 PM logoThe Psychiatry Pipeline Of Supernus Looks Promising - May 31 at 12:14 PM logoSupernus Pharmaceuticals Inc (SUPN) VP Sells $89,750.00 in Stock - May 30 at 10:21 PM logoSupernus Pharmaceuticals Inc (SUPN) Expected to Post Quarterly Sales of $66.93 Million - May 28 at 8:02 AM logoSupernus Pharmaceuticals Inc (SUPN) VP Sells $191,950.00 in Stock - May 25 at 10:21 PM logoEdited Transcript of SUPN earnings conference call or presentation 10-May-17 1:00pm GMT - May 16 at 8:54 AM logoSunTrust Banks Weighs in on Supernus Pharmaceuticals Inc's Q2 2017 Earnings (SUPN) - May 15 at 7:26 AM logoSupernus Pharmaceuticals Inc (SUPN) Receives Consensus Rating of "Buy" from Analysts - May 12 at 2:38 PM logoEquities Analysts Issue Forecasts for Supernus Pharmaceuticals Inc's FY2017 Earnings (SUPN) - May 12 at 12:32 PM logoSupernus Pharmaceuticals Inc (SUPN) Stock Rating Reaffirmed by Cantor Fitzgerald - May 11 at 9:02 PM logoCowen and Company Reiterates Outperform Rating for Supernus Pharmaceuticals Inc (SUPN) - May 11 at 4:46 PM logoJefferies Group LLC Reiterates $35.00 Price Target for Supernus Pharmaceuticals Inc (SUPN) - May 11 at 2:56 PM logoSupernus Pharmaceuticals Inc (SUPN) Expected to Earn FY2017 Earnings of $0.87 Per Share - May 11 at 10:52 AM logoSupernus Pharmaceuticals Inc (SUPN) Issues Earnings Results, Misses Estimates By $0.03 EPS - May 10 at 6:20 PM



Supernus Pharmaceuticals (SUPN) Chart for Saturday, July, 22, 2017

This page was last updated on 7/22/2017 by Staff